CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

Update: 2025-01-15

Description

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice.

CME information and select publications here.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

2025-01-2259:32

Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer

2025-01-1701:00:59

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2025-01-1502:00:29

Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2025-01-1301:59:15

Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3

2025-01-1002:01:00

Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2025-01-0801:27:00

Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2025-01-0601:58:51

The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2

2025-01-0302:00:37

HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1

2024-12-2301:31:29

Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2024-12-2001:57:11

Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

2024-12-1801:57:07

Cases from the Community: Integrating New Research Findings into Current Practice — Colorectal and Gastroesophageal Cancers

2024-12-1849:11

Cases from the Community: Integrating New Research Findings into Current Practice — Hepatobiliary Cancers

2024-12-1855:50

Cases from the Community: Integrating New Research Findings into Current Practice — Gynecologic Cancers

2024-12-1746:41

Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

2024-12-1751:43

Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic Syndromes

2024-12-1351:45

Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer

2024-12-1348:03

5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

2024-12-1311:59

Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review

2024-12-1058:47

Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer

2024-12-0459:42

00:00

1.0x

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

#box-pro-ellipsis-173769730782314{-webkit-line-clamp:2;}CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

Research To Practice

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series